mitomycin has been researched along with Leiomyosarcoma, Epithelioid in 13 studies
Mitomycin: An antineoplastic antibiotic produced by Streptomyces caespitosus. It is one of the bi- or tri-functional ALKYLATING AGENTS causing cross-linking of DNA and inhibition of DNA synthesis.
mitomycin : A family of aziridine-containing natural products isolated from Streptomyces caespitosus or Streptomyces lavendulae.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 9.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Adult patients with advanced leiomyosarcomas received intravenous chemotherapy as outpatients with dacarbazine 750 micrograms/m2, mitomycin 6 mg/m2, doxorubicin 40 mg/m2, and cisplatin 60 mg/m2 on day 0, with granulocyte macrophage colony stimulating factor (GM-CSF, sagramostim) 250 mcg/m2 given s." | 9.10 | Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. ( Buckner, JC; Edmonson, JH; Mahoney, MR; Marks, RS, 2002) |
| "Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease." | 9.10 | Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Cohn, DE; Cosin, JA; Edmonson, JH; Miller, DS; Rotmensch, J, 2002) |
| "In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial." | 7.67 | Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. ( Creagan, ET; Edmonson, JH; Green, SJ; Long, HJ; Richardson, RL, 1985) |
| "Following a reported 23% response rate (RR) for mitomycin (M), doxorubicin (A), and cisplatin (P) and preliminary data suggesting a superior RR for dacarbazine (D) + MAP + sargramostim, the Gynecologic Oncology Group (GOG) conducted a phase II trial of DMAP + sargramostim in patients with advanced uterine leiomyosarcoma." | 5.11 | Phase II trial of dacarbazine, mitomycin, doxorubicin, and cisplatin with sargramostim in uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Long, HJ; Sorosky, J, 2005) |
| "Adult patients with advanced leiomyosarcomas received intravenous chemotherapy as outpatients with dacarbazine 750 micrograms/m2, mitomycin 6 mg/m2, doxorubicin 40 mg/m2, and cisplatin 60 mg/m2 on day 0, with granulocyte macrophage colony stimulating factor (GM-CSF, sagramostim) 250 mcg/m2 given s." | 5.10 | Contrast of response to dacarbazine, mitomycin, doxorubicin, and cisplatin (DMAP) plus GM-CSF between patients with advanced malignant gastrointestinal stromal tumors and patients with other advanced leiomyosarcomas. ( Buckner, JC; Edmonson, JH; Mahoney, MR; Marks, RS, 2002) |
| "Because of preliminary observations favoring the use of mitomycin, doxorubicin, and cisplatin (MAP) chemotherapy in leiomyosarcomas, the Gynecologic Oncology Group (GOG) decided to conduct a phase II clinical trial of this combination regimen in patients with advanced disease." | 5.10 | Phase II study of mitomycin, doxorubicin, and cisplatin in the treatment of advanced uterine leiomyosarcoma: a Gynecologic Oncology Group study. ( Blessing, JA; Cohn, DE; Cosin, JA; Edmonson, JH; Miller, DS; Rotmensch, J, 2002) |
| "A patient with mitomycin-associated hemolytic-uremic syndrome received SPA treatments after her ACE inhibitor, lisinopril, was held." | 3.71 | Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation. ( Adam, A; Eastlund, T; Hammerschmidt, D; Koenigbauer, U; Lepage, Y; Molinaro, G, 2002) |
| "In all 63 patients were treated monthly with a combination of mitomycin, doxorubicin, and cisplatin, and 27 (43%) experienced objective regression of their advanced sarcomas during a 3-month trial." | 3.67 | Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. ( Creagan, ET; Edmonson, JH; Green, SJ; Long, HJ; Richardson, RL, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (15.38) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Baratti, D | 1 |
| Pennacchioli, E | 1 |
| Kusamura, S | 1 |
| Fiore, M | 1 |
| Balestra, MR | 1 |
| Colombo, C | 1 |
| Mingrone, E | 1 |
| Gronchi, A | 1 |
| Alessanrdro, G | 1 |
| Deraco, M | 1 |
| Baumgartner, JM | 1 |
| Ahrendt, SA | 1 |
| Pingpank, JF | 1 |
| Holtzman, MP | 1 |
| Ramalingam, L | 1 |
| Jones, HL | 1 |
| Zureikat, AH | 1 |
| Zeh, HJ | 1 |
| Bartlett, DL | 1 |
| Choudry, HA | 1 |
| Edmonson, JH | 3 |
| Marks, RS | 1 |
| Buckner, JC | 1 |
| Mahoney, MR | 1 |
| Molinaro, G | 1 |
| Adam, A | 1 |
| Lepage, Y | 1 |
| Hammerschmidt, D | 1 |
| Koenigbauer, U | 1 |
| Eastlund, T | 1 |
| Mohindra, A | 1 |
| Bolderson, E | 1 |
| Stone, J | 1 |
| Wells, M | 1 |
| Helleday, T | 1 |
| Meuth, M | 1 |
| Long, HJ | 2 |
| Blessing, JA | 2 |
| Sorosky, J | 1 |
| Dispenzieri, A | 1 |
| Loprinzi, CL | 1 |
| Yokota, T | 1 |
| Abe, Y | 1 |
| Itoh, J | 1 |
| Kunori, T | 1 |
| Mochizuki, M | 1 |
| Asano, S | 1 |
| Shinya, F | 1 |
| Rajan, DK | 1 |
| Soulen, MC | 1 |
| Clark, TW | 1 |
| Baum, RA | 1 |
| Haskal, ZJ | 1 |
| Shlansky-Goldberg, RD | 1 |
| Freiman, DB | 1 |
| Cosin, JA | 1 |
| Miller, DS | 1 |
| Cohn, DE | 1 |
| Rotmensch, J | 1 |
| Matsumoto, M | 1 |
| Goshima, H | 1 |
| Yamazaki, Y | 1 |
| Kokehara, N | 1 |
| Oota, M | 1 |
| Ishida, N | 1 |
| Itou, F | 1 |
| Richardson, RL | 1 |
| Creagan, ET | 1 |
| Green, SJ | 1 |
| Senapad, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Evaluation of DMAP Plus GM-CSF in the Treatment of Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus[NCT00033644] | Phase 2 | 0 participants | Interventional | 2002-03-31 | Terminated | ||
| Evaluation of Mitomycin, Doxorubicin and Cisplatin in the Treatment of Recurrent or Advanced Uterine Sarcomas[NCT00002993] | Phase 2 | 30 participants (Anticipated) | Interventional | 1997-08-31 | Terminated | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 trials available for mitomycin and Leiomyosarcoma, Epithelioid
10 other studies available for mitomycin and Leiomyosarcoma, Epithelioid
| Article | Year |
|---|---|
Peritoneal sarcomatosis: is there a subset of patients who may benefit from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy?
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Cancer, Regional Perfusio | 2010 |
Aggressive locoregional management of recurrent peritoneal sarcomatosis.
Topics: Adolescent; Adult; Aged; Analysis of Variance; Antineoplastic Combined Chemotherapy Protocols; Chemo | 2013 |
Hypotensive reaction during staphylococcal protein A column therapy in a patient with anomalous degradation of bradykinin and Des-Arg9-bradykinin after contact activation.
Topics: Acute Disease; Aminopeptidases; Angiotensin-Converting Enzyme Inhibitors; Antineoplastic Combined Ch | 2002 |
A tumour-derived mutant allele of XRCC2 preferentially suppresses homologous recombination at DNA replication forks.
Topics: Base Pair Mismatch; Camptothecin; DNA; DNA Repair; DNA Replication; DNA-Binding Proteins; Female; Ge | 2004 |
Chemotherapy-induced insulin-dependent diabetes mellitus.
Topics: Antiemetics; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Dacarbazine; Dexamethasone; | 1997 |
Epithelioid leiomyosarcoma of the stomach: report of a case.
Topics: Abdominal Pain; Angiography, Digital Subtraction; Antibiotics, Antineoplastic; Biopsy; Combined Moda | 2000 |
Sarcomas metastatic to the liver: response and survival after cisplatin, doxorubicin, mitomycin-C, Ethiodol, and polyvinyl alcohol chemoembolization.
Topics: Chemoembolization, Therapeutic; Cisplatin; Disease Progression; Doxorubicin; Ethiodized Oil; Female; | 2001 |
[A case of unresectable liver metastasis from leiomyosarcoma of the stomach successfully treated by intra hepato-arterial chemotherapy with Infuse-A-Port].
Topics: Antineoplastic Combined Chemotherapy Protocols; Doxorubicin; Fluorouracil; Hepatic Artery; Humans; I | 1990 |
Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Doxorubicin; Dru | 1985 |
Chemotherapy for gynecologic malignancies at Siriraj Hospital, Bangkok.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Squamous Cell; Cisplatin; Cyclophosphamid | 1985 |